Degarelix acetate. GnRH antagonist, prostate cancer therapy

Drugs of the Future

Volumn 31, Issue 9, 2006, Pages 755-766

  Sorbera, L A ^a   Bolos J ^a   Serradell, N ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; AZALINE B; CETRORELIX; DEGARELIX ACETATE; FE 200486; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; N ACETYL 3 (2 NAPHTHYL)DEXTRO ALANYL 4 CHLORO DEXTRO PHENYLALANYL 3 (3 PYRIDYL)DEXTRO ALANYLSERYL 4 (2,6 DIOXOHEXAHYDROPYRIMIDIN 4 YLCARBOXAMIDO)PHENYLALANYL 4 UREIDO DEXTRO PHENYLALANYLLEUCYL N 6 ISOPROPYLLYSYLPROLYL DEXTRO ALANINAMIDE ACETATE; OZARELIX; POLYGLACTIN; TESTOSTERONE; TEVERELIX;

ALLERGIC REACTION; ARTICLE; BREAST TUMOR; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENZYMATIC DEGRADATION; ERYTHEMA; HISTAMINE RELEASE; HORMONE SYNTHESIS; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; MAINTENANCE DRUG DOSE; METASTASIS INHIBITION; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; SIDE EFFECT; SLOW RELEASE FORMULATION; STEROIDOGENESIS; SUSTAINED DRUG RELEASE; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 33845323027     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.09.1024366     Document Type: Article

References (38)

1. Semple, G., Jiang, G. (Ferring BV). GnRH antagonists being modified in positions 5 and 6. JP 2001523229, JP 2005120101, WO 9846634.
2. Jiang, G., Stalewski, J., Galyean, R. et al. GnRH antagonists: A new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001, 44(3): 453-67.
3. Prous Science Drug R&D Backgrounders: Prostate Cancer (online publication). Updated July 13, 2006.
4. Parkin, D.M. et al. Global cancer statistics, 2002. CA - Cancer J Clin 2005, 55(2): 74-108.
5. Isaacs, J.T. Apoptosis: Translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000, 92(17): 1367-9.
6. Debes, J.D., Tindall, D.J. Mechanisms of androgen-refractory prostate cancer. New Engl J Med 2004, 351(15): 1488-90.
7. Dondi, D., Festuccia, C., Piccolella, M., Bologna, M., Motta, M. GnRH agonists and antagonists decrease the metatastic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 2006, 15(2): 393-400.
8. Schally, A.V., Arimura, A., Kastin, A.J. et al. Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle stimulating hormones. Science 1971, 173: 1036-8.
9. Huirne, J.A., Lambalk, C.B. Gonadotropin-releasing hormone-receptor antagonists. Lancet 2001, 358: 1793-803.
10. Blithe, D.L. Applications for GnRH antagonists. Trends Endrocrinol Metab 2001, 12(6): 238-40.
11. Rivier, J. GnRH analogues: Recent developments. Infert Reprod Med Clin N Am 2001, 12(1): 233-45.
12. Broqua, P., Riviere, P.J.-M., Conn, P.M., Rivier, J.E., Aubert, M.L., Junien, J.-L. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. J Pharmacol Exp Ther 2002, 301(1): 95-102.
13. Broqua, P., Aebi, A., Jiang, G.C. et al. Pharmacological profile of FE200486, a potent, water soluble and long acting GnRH antagonist. Gynecol Endocrinol 1999, 13(Suppl, 1): Abst 018.
14. Broqua, P., Akinsanya, K., Riviere, P., Conn, P.M., Rivier, J., Aubert, M., Junien, J.-L. Pharmacological profile in the rat and monkey of a new, potent and long-acting GnRH antagonist: FE 200486. 82nd Annu Meet Endocr Soc (June 21-24, Toronto) 2000, Abst 498.
15. Koechling, W. Effect of various GnRH antagonists on histamine release from human skin. 8th Int Symp GnRH Analogues Cancer Hum Reprod (Feb 10-13, Salzburg) 2005, Abst.
16. Princivalle, M., Broqua, P., White, R. et al. Rapid suppression of plasma testosterone levels and tumour growth in rats treated with degarelix, a new GnRH antagonist. 8th Int Symp GnRH Analogues Cancer Hum Reprod (Feb 10-13, Salzburg) 2005, Abst.
17. Broqua, P., France, D., Bichat, F., Genne, P., Aubert, M.L., Junien, J.-L. Rapid and long-lasting suppression of plasma testosterone levels in the rat by the new GnRH antagonist Fe 200486: Impact on growth of the androgen-dependent rat prostate tumor Dunning R-3327H. 82nd Annu Meet Endocr Soc (June 21-24, Toronto) 2000, Abst 697.
18. Princivalle, M., Broqua, P., White, R. et al. Anti-tumour activity of degarelix, a new GnRH antagonist, on DMBA-induced rat mammary tumours. 8th Int Symp GnRH Analogues Cancer Hum Reprod (Feb 10-13, Salzburg) 2005, Abst.
19. Schwach, G., Oudry, N., Delhomme, S., Lück, M., Lindner, H., Gurny, R. Biodegradable microparticles for sustained release of a new GnRH antagonist - Part I: Screening commercial PLGA and formulation technologies. Eur J Pharm Biopharm 2003, 56(3): 327-36.
20. Schwach, G., Oudry, N, Giliberto, J.-P., Broqua, P., Lück, M., Lindner, H., Gurny, R. Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: Part II. In vivo performance. Eur J Pharm Biopharm 2004, 57(3): 441-6.
21. Agerse, H., Koechling, W., Knutsson, M., Hjortkjaer, R., Karlsson, M.O. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Eur J Pharm Sci 2003, 20(3): 335-40.
22. Tornøe, C.W., Agersø, H., Nielsen, H.A., Madsen, H., Jonsson, E.N. Pharmacokinetic/pharmacodynamic modeling of GnRH antagonist degarelix: A comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet Pharmacodyn 2004, 31(6): 441-61.
23. Tornøe, C.W., Agersø, H., Nielsen, H.A., Madsen, H., Jonsson, E.N. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degareliex. Pharm Res 2004, 21(4): 574-84.
24. Svensson, U.S.H., Senderovitz, T., Karlsson, M.O. Population PK/PD modeling of testosterone (T). LH and dihydrotestosterone (DHT) response to single s.c. degarelix in male volunteers. Clin Pharmacol Ther 2003, 73(2): Abst PIII-92.
25. Balchen, T., Agersø, H., Olesen, T.K., Jensen, J.-K., Senderovitz, T. Pharmacokinetics, pharmacodynamics, and safety of a novel fast-acting gonadotorpin-releasing hormone receptor blocker, degarelix, in healthy men. 8th Int Symp GnRH Analogues Cancer Hum Reprod (Feb 10-13, Salzburg) 2005, Abst.
26. Balchen, T., Agersø, H., Wu, F., Iversen, P., Jensen, J.-K., Lovgren, U., Senderovitz, T. Single subcutaneous administration of a novel, fast-acting gonadotropin-releasing hormone (GnRH) antagonist degarelix (FE200486) with depot characteristics in healthy men. Clin Exp Pharmacol Physiol 2004, 31(Suppl.): Abst PO-288.
27. Tammela, T., Iversen, P., Johansson, J., Persson, B., Jensen, J., Olesen, T. Degarelix Study Group. Degarelix - A phase II multicentre, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients. Eur Urol Suppl [20th Congr Eur Assoc Urol (March 16-19, Istanbul) 2005] 2005, 4(3): Abst 904.
28. Persson, B.-E., Hammonds, J., Weston, P.M.T., Vaughton, K., Jensen, J.-K., Eskerod, O., Olesen, T.K. Degarelix: A novel GnRH receptor blocker tested in a multicenter, randomized dose-finding study in prostate cancer patients. 8th Int Symp GnRH Analogues Cancer Hum Reprod (Feb 10-13, Salzburg) 2005, Abst.
29. Weston, P., Hammonds, J., Vaughton, K., Olesen, T.K., Jensen, J.K., Eskerod, O., Persson, B.E. Degarelix: A novel GnRH antagonist tested in a multicenter, randomized dose-finding study in prostate cancer patients. 27th Congr Soc Int Urol (Oct 3-7, Honolulu) 2004, Abst PD-4.03.
30. Tombal, B., De La Rosette, J., Persson, B., Jensen, J., Olesen, T. Testosterone and PSA response in a one-year, multi-centre, randomised study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in patients with prostate cancer (CaP). Prostate Cancer Symp (Feb 24-26, San Francisco) 2006, Abst 187.
31. Van Poppel, H., De La Rosette, J., Persson, B.E., Jensen, J.K., Olesen, T.K. A one-year, multicentre, randomised study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients. Eur Urol Suppl [21st Congr Eur Assoc Urol (April 5-8, Paris) 2006] 2006, 5(2): Abst 915.
32. An open-label, multi-centre, extension study (NCT00268892). ClinicalTrials.gov Web site 2006.
33. An open-label, multi-center, extension study investigating the long-term safety and tolerability of repeat doses of FE200486 in prostate cancer patients (NCT00215657). ClinicalTrials.gov Web site 2006.
34. Study investigating the long-term safety and tolerability of repeated doses of FE 200486 in prostate cancer patients (NCT00245466). ClinicalTrials.gov Web site 2006.
35. An open-label, multi-centre, extension study evaluating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer (NCT00215683). ClinicalTrials.gov Web site 2006.
36. Extension study investigating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer (NCT00117286). ClinicalTrials.gov Web site 2006.
37. A comparative study of degarelix three-month depot in three different dosing regimens in patients with prostate cancer (NCT00116753). ClinicalTrials.gov Web site 2006.
38. Study, investigating the efficacy and safety of degarelix one month dosing regimens (NCT00295750). ClinicalTrials.gov Web site 2006.